Electrophoresis mobility shift assay and biosensor used in studying the interaction between Bleomycin A5 (cas 11116-32-8) and DNA

Add time:07/20/2019    Source:sciencedirect.com

DNA is the potential target of numerous drugs utilized widely in clinical cancer therapy. Here we employed Bleomycin A5 (cas 11116-32-8), with its deactivated form as contrast, to investigate the interaction between small pharmaceutical and DNA. Electrophoresis mobility shift assay (EMSA) which is a common technique used in studying specific interactions between DNA and proteins is applied in visualizing the binding of bleomycin A5 with DNA intuitively. More accurate association equilibrium constant for native and deactivated bleomycin A5 to DNA achieved on biosensor IAsys AUTO+ is 1.25 × 104 and 1.3 × 103 M−1, respectively. With combination of EMSA and biosensor, a qualitative and quantitative method is described, which can be extended to studying the binding of most small molecules with targeting DNA and serves as a powerful tool in designing and screening for novel drugs.

We also recommend Trading Suppliers and Manufacturers of Bleomycin A5 (cas 11116-32-8). Pls Click Website Link as below: cas 11116-32-8 suppliers

Prev:Bleomycin A5 (cas 11116-32-8) plus dexamethasone for control of growth in infantile parotid hemangiomas
Next:A clinical study of ultrasound-guided intralesional injection of Bleomycin A5 (cas 11116-32-8) on venous malformation in cervical-facial region in China)